
Opinion|Videos|February 5, 2024
Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy
Experts underscore cost relief of bispecific antibodies via medication assistance programs.
Advertisement
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Barriers to Treatment in Pediatric Myasthenia Gravis: Jonathan Strober, MD
2
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
3
Defining Relapse and Switching Therapies in Multiple Myeloma
4
Evidence for GLP-1 Therapy in MASH
5













































